Trepo - Selaus tekijän mukaan "C4591007 Clinical Trial Group"

Viitteet 1-1 / 1

    • Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds 

      C4591007 Clinical Trial Group; Simões, Eric A.F.; Klein, Nicola P.; Sabharwal, Charu; Gurtman, Alejandra; Kitchin, Nicholas; Ukkonen, Benita; Korbal, Piotr; Zou, Jing; Xie, Xuping; Sarwar, Uzma N.; Xu, Xia; Lockhart, Stephen; Cunliffe, Luke; Lu, Claire; Ma, Hua; Swanson, Kena A.; Koury, Kenneth; Shi, Pei Yong; Cooper, David; Türeci, Ozlem; Jansen, Kathrin U.; Şahin, Uğur; Gruber, William C. (03 / 2023)
      article
      In this ongoing study, substantially increased ancestral SARSCoV-2 neutralizing responses were observed 1 month after a third 10-µg BNT162b2 dose given to 5 to 11-year olds versus neutralizing responses post-dose 2. After ...